Regarding OS, CV was associated with significantly lower risk of death independently of other relevant clinical or tumor-related variables, with the survival advantage being limited to patients with HR+ BC, and in particular to patients with ER+ PgR+ disease. This evidence concerns the gene ESR1 and breast cancer.